Advances in pharmacotherapies for cytomegalovirus infection: what is the current state of play?

References

• Forte E, Zhang Z, Thorp EB, Hummel M. Cytomegalovirus latency and reactivation: an intricate interplay with the Host immune response. Frontiers in cellular and infection microbiology. 2020;10:130. doi: 10.3389/fcimb.2020.00130 Epub 2020/04/17. PubMed PMID: 32296651; PubMed Central PMCID: PMCPMC7136410.
   PubMed Web of Science ®Google Scholar
• Cannon MJ, Schmid DS, Hyde TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection. Rev Med Virol. 2010;20(4):202–213. doi: 10.1002/rmv.655 Epub 2010/06/22. PubMed PMID: 20564615.
   PubMed Web of Science ®Google Scholar
• Arcangeletti MC, Vasile Simone R, Rodighiero I, et al. Human cytomegalovirus reactivation from latency: validation of a “switch” model in vitro. Virol J. 2016;13(1):179. doi: 10.1186/s12985-016-0634-z Epub 2016/10/25. PubMed PMID: 27770817; PubMed Central PMCID: PMCPMC5075216.
   PubMedGoogle Scholar
• Ariza-Heredia EJ, Nesher L, Chemaly RF. Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review. Cancer Lett. 2014;342(1):1–8. doi: 10.1016/j.canlet.2013.09.004 Epub 2013/09/18. PubMed PMID: 24041869.
   PubMed Web of Science ®Google Scholar
• Avery RK, Arav-Boger R, Marr KA, et al. Outcomes in transplant recipients treated with foscarnet for ganciclovir-resistant or refractory cytomegalovirus infection. Transplantation. 2016;100(10):e74–80. doi: 10.1097/tp.0000000000001418 Epub 2016/08/09. PubMed PMID: 27495775; PubMed Central PMCID: PMCPMC5030152.
   PubMed Web of Science ®Google Scholar
• Beam E, Lesnick T, Kremers W, et al. Cytomegalovirus disease is associated with higher all-cause mortality after lung transplantation despite extended antiviral prophylaxis. Clin Transplant. 2016;30(3):270–278. doi: 10.1111/ctr.12686 Epub 2015/12/25 PubMed PMID: 26701733.
   PubMed Web of Science ®Google Scholar
• Felipe CR, Ferreira AN, Bessa A, et al. The current burden of cytomegalovirus infection in kidney transplant recipients receiving no pharmacological prophylaxis. J brasileiro de nefrologia. 2017;39(4):413–423. doi: 10.5935/0101-2800.20170074 Epub 2018/01/11 PubMed PMID: 29319768.
   PubMedGoogle Scholar
• Haidar G, Boeckh M, Singh N. Cytomegalovirus infection in solid organ and hematopoietic cell transplantation: state of the evidence. J Infect Dis. 2020;221(Suppl 1):S23–s31. doi: 10.1093/infdis/jiz454 Epub 2020/03/07 PubMed PMID: 32134486; PubMed Central PMCID: PMCPMC7057778.
   PubMedGoogle Scholar
• Teira P, Battiwalla M, Ramanathan M, et al. Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis. Blood. 2016;127(20):2427–2438. doi: 10.1182/blood-2015-11-679639 Epub 2016/02/18 PubMed PMID: 26884374; PubMed Central PMCID: PMCPMC4874224.
   PubMed Web of Science ®Google Scholar
• Kotton CN, Kumar D, Caliendo AM, et al. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation. 2018;102(6):900–931. doi: 10.1097/tp.0000000000002191 Epub 2018/03/30 PubMed PMID: 29596116.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Boeckh M, Hirsch HH, et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials: table 1. Clin Infect Dis. 2017;64(1):87–91. doi: 10.1093/cid/ciw668 Epub 2016/10/30 PubMed PMID: 27682069.
   PubMed Web of Science ®Google Scholar
• Razonable RR, Humar A. Cytomegalovirus in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):93–106. doi: 10.1111/ajt.12103 Epub 2013/03/08 PubMed PMID: 23465003.
   PubMedGoogle Scholar
• Green ML, Leisenring W, Xie H, et al. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. Lancet Haematol. 2016;3(3):e119–27. doi: 10.1016/s2352-3026(15)00289-6 Epub 2016/03/08 PubMed PMID: 26947200; PubMed Central PMCID: PMCPMC4914379.
   PubMed Web of Science ®Google Scholar
• Stern M, Hirsch H, Cusini A, et al. Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment. Transplantation. 2014;98(9):1013–1018. doi: 10.1097/tp.0000000000000160 Epub 2014/05/20 PubMed PMID: 24837540.
   PubMed Web of Science ®Google Scholar
• Eid AJ, Razonable RR. New developments in the management of cytomegalovirus infection after solid organ transplantation. Drugs. 2010;70(8):965–981. doi: 10.2165/10898540-000000000-00000 Epub 2010/05/21 PubMed PMID: 20481654.
   PubMed Web of Science ®Google Scholar
• Cho SY, Lee DG, Kim HJ. Cytomegalovirus infections after hematopoietic stem cell transplantation: Current status and future immunotherapy. Int J Mol Sci. 2019;20(11). doi: 10.3390/ijms20112666 Epub 2019/06/04 PubMed PMID: 31151230; PubMed Central PMCID: PMCPMC6600658.
   Web of Science ®Google Scholar
• Camargo JF, Komanduri KV. Emerging concepts in cytomegalovirus infection following hematopoietic stem cell transplantation. Hematol Oncol Stem Cell Ther. 2017;10(4):233–238. doi: 10.1016/j.hemonc.2017.05.001 Epub 2017/06/24 PubMed PMID: 28641094.
   PubMedGoogle Scholar
• Boeckh M, Ljungman P. How we treat cytomegalovirus in hematopoietic cell transplant recipients. Blood. 2009;113(23):5711–5719. doi: 10.1182/blood-2008-10-143560 Epub 2009/03/21 PubMed PMID: 19299333; PubMed Central PMCID: PMCPMC2700312.
   PubMed Web of Science ®Google Scholar
• Camargo JF, Kimble E, Rosa R, et al. Impact of cytomegalovirus viral load on probability of spontaneous clearance and response to preemptive therapy in allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2018;24(4):806–814. doi: 10.1016/j.bbmt.2017.11.038 Epub 2017/12/09 PubMed PMID: 29217388.
   PubMed Web of Science ®Google Scholar
• Gea-Banacloche J. Risks and Epidemiology of Infections After Hematopoietic Stem Cell Transplantation. Transplant Infections. 2016 Feb 15;81–99. doi: 10.1007/978-3-319-28797-3_6. PMCID: PMC7124050.
   Google Scholar
• Chan ST, Logan AC. The clinical impact of cytomegalovirus infection following allogeneic hematopoietic cell transplantation: why the quest for meaningful prophylaxis still matters. Blood Rev. 2017;31(3):173–183. doi: 10.1016/j.blre.2017.01.002 Epub 2017/02/09 PubMed PMID: 28173959.
   PubMed Web of Science ®Google Scholar
• Ljungman P, Hakki M, Boeckh M. Cytomegalovirus in hematopoietic stem cell transplant recipients. Hematol Oncol Clin North Am. 2011;25(1):151–169. Epub 2011/01/18. doi: 10.1016/j.hoc.2010.11.011 PubMed PMID: 21236396; PubMed Central PMCID: PMCPMC3340426.
   PubMed Web of Science ®Google Scholar
• Razonable RR, Humar A. Cytomegalovirus in solid organ transplant recipients-guidelines of the American society of transplantation infectious diseases community of practice. Clin Transplant. 2019;33(9):e13512. Epub 2019/03/01. doi: 10.1111/ctr.13512 PubMed PMID: 30817026.
   PubMed Web of Science ®Google Scholar
• Zavras P, Su Y, Fang J, et al. Impact of preemptive therapy for cytomegalovirus on toxicities after allogeneic hematopoietic cell transplantation in clinical practice: a retrospective single-center cohort study. Biol Blood Marrow Transplant. 2020;26(8):1482–1491. Epub 2020/04/22. doi: 10.1016/j.bbmt.2020.03.019 PubMed PMID: 32315708; PubMed Central PMCID: PMCPMC8220837.
   PubMed Web of Science ®Google Scholar
• Khawaja F, Batista MV, El Haddad L, et al. Resistant or refractory cytomegalovirus infections after hematopoietic cell transplantation: diagnosis and management. Curr Opin Infect Dis. 2019;32(6):565–574. Epub 2019/10/01. doi: 10.1097/qco.0000000000000607 PubMed PMID: 31567572.
   PubMed Web of Science ®Google Scholar
• Upadhyayula S, Ganciclovir MM. Foscarnet, and cidofovir: antiviral drugs not just for cytomegalovirus. J Pediatric Infect Dis Soc. 2013;2(3):286–290. doi: 10.1093/jpids/pit048
   PubMedGoogle Scholar
• Marshall BC, Koch WC. Antivirals for cytomegalovirus infection in neonates and infants: focus on pharmacokinetics, formulations, dosing, and adverse events. Paediatr Drugs. 2009;11(5):309–321. Epub 2009/09/04. doi: 10.2165/11316080-000000000-00000 PubMed PMID: 19725597.
   PubMedGoogle Scholar
• Schleiss MR. Antiviral therapy of congenital cytomegalovirus infection. Semin Pediatr Infect Dis. 2005;16(1):50–59. Epub 2005/02/03. doi: 10.1053/j.spid.2004.09.012 PubMed PMID: 15685150.
   PubMedGoogle Scholar
• Imlay HN, Kaul DR. Letermovir and Maribavir for the treatment and prevention of cytomegalovirus infection in solid organ and stem cell transplant recipients. Clin Infect Dis. 2021;73(1):156–160. Epub 2020/11/17. doi: 10.1093/cid/ciaa1713 PubMed PMID: 33197929.
   PubMed Web of Science ®Google Scholar
• Xiong X, Smith JL, Chen MS. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation. Antimicrob Agents Chemother. 1997;41(3):594–599. Epub 1997/03/01. doi: 10.1128/aac.41.3.594 PubMed PMID: 9055999; PubMed Central PMCID: PMCPMC163757.
   PubMed Web of Science ®Google Scholar
• Marty FM, Winston DJ, Chemaly RF, et al. A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019;25(2):369–381. Epub 2018/10/08. doi: 10.1016/j.bbmt.2018.09.038 PubMed PMID: 30292744; PubMed Central PMCID: PMCPMC8196624.
   PubMed Web of Science ®Google Scholar
• Wagstaff AJ, Bryson HF. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs. 1994;48(2):199–226. Epub 1994/08/01. doi: 10.2165/00003495-199448020-00007 PubMed PMID: 7527325.
   PubMed Web of Science ®Google Scholar
• Ligat G, Cazal R, Hantz S, et al. The human cytomegalovirus terminase complex as an antiviral target: a close-up view. FEMS Microbiol Rev. 2018;42(2):137–145. Epub 2018/01/24. doi: 10.1093/femsre/fuy004 PubMed PMID: 29361041; PubMed Central PMCID: PMCPMC5972660.
   PubMed Web of Science ®Google Scholar
• Razonable RR. Role of letermovir for prevention of cytomegalovirus infection after allogeneic haematopoietic stem cell transplantation. Curr Opin Infect Dis. 2018;31(4):286–291. Epub 2018/05/11. doi: 10.1097/qco.0000000000000459 PubMed PMID: 29746444.
   PubMed Web of Science ®Google Scholar
• Chou S. Rapid in vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance. Antimicrob Agents Chemother. 2015;59(10):6588–6593. Epub 2015/08/12. doi: 10.1128/aac.01623-15 PubMed PMID: 26259791; PubMed Central PMCID: PMCPMC4576131.
   PubMed Web of Science ®Google Scholar
• El Helou G, Razonable RR. Letermovir for the prevention of cytomegalovirus infection and disease in transplant recipients: an evidence-based review. Infect Drug Resist. 2019;12:1481–1491. Epub 2019/06/27. doi: 10.2147/idr.S180908 PubMed PMID: 31239725; PubMed Central PMCID: PMCPMC6556539.
   PubMed Web of Science ®Google Scholar
• Lischka P, Michel D, Zimmermann H. Characterization of cytomegalovirus breakthrough events in a phase 2 prophylaxis trial of letermovir (AIC246, MK 8228). J Infect Dis. 2016;213(1):23–30. Epub 2015/06/27. doi: 10.1093/infdis/jiv352 PubMed PMID: 26113373.
   PubMed Web of Science ®Google Scholar
• Perchetti GA, Biernacki MA, Xie H, et al. Cytomegalovirus breakthrough and resistance during letermovir prophylaxis. Bone Marrow Transplant. 2023;58(4):430–436. Epub 2023/01/25. doi: 10.1038/s41409-023-01920-w PubMed PMID: 36693927.
   PubMed Web of Science ®Google Scholar
• Frietsch JJ, Michel D, Stamminger T, et al. In vivo emergence of UL56 C325Y cytomegalovirus resistance to letermovir in a patient with acute myeloid leukemia after hematopoietic cell transplantation. Mediterr J Hematol Infect Dis. 2019;11(1):e2019001. Epub 2019/01/24. doi: 10.4084/mjhid.2019.001 PubMed PMID: 30671207; PubMed Central PMCID: PMCPMC6328044.
   PubMedGoogle Scholar
• Marty FM, Ljungman P, Chemaly RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377(25):2433–2444. Epub 2017/12/07. doi: 10.1056/NEJMoa1706640 PubMed PMID: 29211658.
   PubMed Web of Science ®Google Scholar
• Marty FM, Ljungman PT, Chemaly RF, et al. Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation. Am J Transplant. 2020;20(6):1703–1711. Epub 2019/12/29. doi: 10.1111/ajt.15764 PubMed PMID: 31883426.
   PubMed Web of Science ®Google Scholar
• PREVYMIS (letermovir). Prescribing information. Rahway (NJ) USA: Merck & Co. Inc; 2023.
   Google Scholar
• McCrea JB, Macha S, Adedoyin A, et al. Pharmacokinetic drug-drug interactions between letermovir and the immunosuppressants cyclosporine, tacrolimus, sirolimus, and Mycophenolate Mofetil. J Clin Pharmacol. 2019;59(10):1331–1339. Epub 2019/04/17. doi: 10.1002/jcph.1423 PubMed PMID: 30990905.
   PubMed Web of Science ®Google Scholar
• Duong A, Sweet A, Jain R, et al. Clinically significant drug interaction: letermovir and voriconazole. J Antimicrob Chemother. 2020;75(3):775–777. Epub 2019/12/05. doi: 10.1093/jac/dkz499 PubMed PMID: 31800049; PubMed Central PMCID: PMCPMC7021092.
   PubMed Web of Science ®Google Scholar
• Marshall WL, McCrea JB, Macha S, et al. Pharmacokinetics and tolerability of letermovir coadministered with azole antifungals (posaconazole or voriconazole) in healthy subjects. J Clin Pharmacol. 2018;58(7):897–904. Epub 2018/03/27. doi: 10.1002/jcph.1094 PubMed PMID: 29578577.
   PubMed Web of Science ®Google Scholar
• Piret J, Boivin G. Clinical development of letermovir and maribavir: overview of human cytomegalovirus drug resistance. Antiviral Res. 2019;163:91–105. Epub 2019/01/29. doi: 10.1016/j.antiviral.2019.01.011 PubMed PMID: 30690043.
   PubMed Web of Science ®Google Scholar
• O’Brien MS, Markovich KC, Selleseth D, et al. In vitro evaluation of current and novel antivirals in combination against human cytomegalovirus. Antiviral Res. 2018;158:255–263. Epub 2018/08/29. doi: 10.1016/j.antiviral.2018.08.015 PubMed PMID: 30153445.
   PubMed Web of Science ®Google Scholar
• Trofe J, Pote L, Wade E, et al. Maribavir: a novel antiviral agent with activity against cytomegalovirus. Ann Pharmacother. 2008;42(10):1447–1457. Epub 2008/08/14. doi: 10.1345/aph.1L065 PubMed PMID: 18698013.
   PubMed Web of Science ®Google Scholar
• Chou S, Marousek GI. Accelerated evolution of maribavir resistance in a cytomegalovirus exonuclease domain II mutant. J Virol. 2008;82(1):246–253. Epub 2007/10/19. doi: 10.1128/jvi.01787-07 PubMed PMID: 17942550; PubMed Central PMCID: PMCPMC2224356.
   PubMed Web of Science ®Google Scholar
• Drew WL, Miner RC, Marousek GI, et al. Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J Clin Virol. 2006;37(2):124–127. Epub 2006/09/12. doi: 10.1016/j.jcv.2006.07.010 PubMed PMID: 16962820.
   PubMed Web of Science ®Google Scholar
• Chou S, Watanabe J. Ganciclovir and maribavir cross-resistance revisited: relative drug susceptibilities of canonical cytomegalovirus mutants. Antiviral Res. 2024;222:105792. Epub 2024/01/02. doi: 10.1016/j.antiviral.2023.105792 PubMed PMID: 38163624; PubMed Central PMCID: PMCPMC10922325.
   PubMed Web of Science ®Google Scholar
• LIVTENCITY (maribavir). Prescribing information. Takeda Pharmaceuticals America. Lexington (MA): Inc; 2021. p. 02421.
   Google Scholar
• Papanicolaou GA, Silveira FP, Langston AA, et al. Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study. Clin Infect Dis. 2019;68(8):1255–1264. Epub 2018/10/18. doi: 10.1093/cid/ciy706 PubMed PMID: 30329038; PubMed Central PMCID: PMCPMC6451997.
   PubMed Web of Science ®Google Scholar
• Maertens J, Cordonnier C, Jaksch P, et al. Maribavir for preemptive treatment of cytomegalovirus reactivation. N Engl J Med. 2019;381(12):1136–1147. Epub 2019/09/19. doi: 10.1056/NEJMoa1714656 PubMed PMID: 31532960.
   PubMed Web of Science ®Google Scholar
• Avery RK, Alain S, Alexander BD, et al. Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial. Clinical infectious diseases: an official publication of the infectious diseases Society of America. 2022;75(4):690–701. Epub 2021/12/06. doi: 10.1093/cid/ciab988 PubMed PMID: 34864943; PubMed Central PMCID: PMCPMC9464078.
   Google Scholar
• Jackson KA, Bohm MK, Brooks JT, et al. Invasive methicillin-resistant Staphylococcus aureus infections among persons who inject drugs - six sites, 2005-2016. MMWR Morb Mortal Wkly Rep. 2018;67(22):625–628. Epub 2018/06/08. doi: 10.15585/mmwr.mm6722a2 PubMed PMID: 29879096; PubMed Central PMCID: PMCPMC5991809 SutroVax, and Shionogi outside the submitted work. No other conflicts of interest were reported.
   PubMed Web of Science ®Google Scholar
• Winston DJ, Young JA, Pullarkat V, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. Blood. 2008;111(11):5403–5410. Epub 2008/02/21. doi: 10.1182/blood-2007-11-121558 PubMed PMID: 18285548; PubMed Central PMCID: PMCPMC5726327.
   PubMed Web of Science ®Google Scholar
• Marty FM, Ljungman P, Papanicolaou GA, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis. 2011;11(4):284–292. Epub 2011/03/19. doi: 10.1016/s1473-3099(11)70024-x PubMed PMID: 21414843.
   PubMed Web of Science ®Google Scholar
• Winston DJ, Saliba F, Blumberg E, et al. Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial. Am J Transplant. 2012;12(11):3021–3030. Epub 2012/09/06. doi: 10.1111/j.1600-6143.2012.04231.x PubMed PMID: 22947426.
   PubMed Web of Science ®Google Scholar
• Halpern-Cohen V, Blumberg EA. New perspectives on antimicrobial agents: Maribavir. Antimicrobial agents and chemotherapy. 2022;66(9):e0240521. Epub 2022/08/03. doi: 10.1128/aac.02405-21 PubMed PMID: 35916518; PubMed Central PMCID: PMCPMC9487637.
   Google Scholar
• Marty FM, Boeckh M. Maribavir and human cytomegalovirus—what happened in the clinical trials and why might the drug have failed? Curr Opin Virol. 2011;1(6):555–562. Epub 2012/03/24. doi: 10.1016/j.coviro.2011.10.011 PubMed PMID: 22440913.
   PubMed Web of Science ®Google Scholar
• Frange P, Leruez-Ville M. Maribavir, brincidofovir and letermovir: efficacy and safety of new antiviral drugs for treating cytomegalovirus infections. Med Mal Infectieuses. 2018;48(8):495–502. Epub 2018/04/14. doi: 10.1016/j.medmal.2018.03.006 PubMed PMID: 29650261.
   PubMed Web of Science ®Google Scholar
• Alain S, Revest M, Veyer D, et al. Maribavir use in practice for cytomegalovirus infection in French transplantation centers. Transplant Proc. 2013;45(4):1603–1607. Epub 2013/06/04. doi: 10.1016/j.transproceed.2013.01.082 PubMed PMID: 23726629.
   PubMed Web of Science ®Google Scholar
• Avery RK, Marty FM, Strasfeld L, et al. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl Infect Dis. 2010;12(6):489–496. Epub 2010/08/05. doi: 10.1111/j.1399-3062.2010.00550.x PubMed PMID: 20682012.
   PubMed Web of Science ®Google Scholar
• Papanicolaou GA, Avery RK, Cordonnier C, et al. Treatment for first cytomegalovirus infection post-hematopoietic cell transplant in the AURORA trial: a multicenter, double-blind, randomized, phase 3 trial comparing maribavir with Valganciclovir. Clin Infect Dis. 2023. Epub 2023/12/01. doi: 10.1093/cid/ciad709 PubMed PMID: 38036487.
   Web of Science ®Google Scholar
• FDA approves first treatment for common type of post-transplant infection that is resistant to other drugs [Internet]. fda.gov; 2021 Nov 23 [cited 2023 Nov 1]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-common-type-post-transplant-infection-resistant-other-drugs
   Google Scholar
• Chou S, Alain S, Cervera C, et al. Drug resistance assessed in a phase 3 clinical trial of maribavir therapy for refractory or resistant cytomegalovirus infection in transplant recipients. The Journal Of Infectious Diseases. 2023;229(2):413–421. doi: 10.1093/infdis/jiad293
   Web of Science ®Google Scholar
• Schubert A, Ehlert K, Schuler-Luettmann S, et al. Fast selection of maribavir resistant cytomegalovirus in a bone marrow transplant recipient. BMC infectious diseases. BMC Infect Dis. 2013;13(1):330. Epub 2013/07/23. doi: 10.1186/1471-2334-13-330 PubMed PMID: 23870704; PubMed Central PMCID: PMCPMC3720178.
   PubMedGoogle Scholar
• Strasfeld L, Lee I, Tatarowicz W, et al. Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir. J Infect Dis. 2010;202(1):104–108. Epub 2010/05/28. doi: 10.1086/653122 PubMed PMID: 20504236.
   PubMed Web of Science ®Google Scholar
• Hakki M, Aitken SL, Danziger-Isakov L, et al. American society for transplantation and cellular therapy series: #3-prevention of cytomegalovirus infection and disease after hematopoietic cell transplantation. Transplant Cell Ther. 2021;27(9):707–719. Epub 2021/08/29. doi: 10.1016/j.jtct.2021.05.001 PubMed PMID: 34452721.
   PubMedGoogle Scholar
• Vyas A, Raval AD, Kamat S, et al. Real-world outcomes associated with letermovir use for cytomegalovirus primary prophylaxis in allogeneic hematopoietic cell transplant recipients: a systematic review and meta-analysis of observational studies. Open forum infectious diseases. 2023;10(1):ofac687. Epub 2023/02/03. doi: 10.1093/ofid/ofac687 PubMed PMID: 36726548; PubMed Central PMCID: PMCPMC9879759.
   Google Scholar
• Chavaz L, Royston L, Masouridi-Levrat S, et al. CMV infection after letermovir primary prophylaxis discontinuation in allogeneic hematopoietic cell transplant recipients. Open forum infectious diseases. 2023;10(4):ofad169. Epub 2023/05/01. doi: 10.1093/ofid/ofad169 PubMed PMID: 37125233; PubMed Central PMCID: PMCPMC10147386.
   Google Scholar
• Liu LW, Yn A, Gao F, et al. Letermovir discontinuation at day 100 after allogeneic stem cell transplant is associated with increased CMV-Related mortality. Transplant Cell Ther. 2022;28(8):.e510.1–.e.9. Epub 2022/05/23. doi: 10.1016/j.jtct.2022.05.020 PubMed PMID: 35598841.
   Google Scholar
• Russo D, Schmitt M, Pilorge S, et al. Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Haematol. 2024;11(2):e127–e35. Epub 2023/12/25. doi: 10.1016/s2352-3026(23)00344-7 PubMed PMID: 38142695.
   PubMed Web of Science ®Google Scholar
• Febres-Aldana AJ, Khawaja F, Spallone A, et al. Duration of letermovir primary prophylaxis in hematopoietic cell transplant recipients at high risk for cytomegalovirus infections and impact on outcomes: open forum infect Dis. Open Forum Infect Dis. 1995 [cited 2023 Nov 27. cited 2023 Nov 27];10(Suppl 2):ofad500.122. doi: 10.1093/ofid/ofad500.122
   Google Scholar
• Limaye AP, Budde K, Humar AV, et al. Letermovir vs valganciclovir for prophylaxis of cytomegalovirus in high-risk kidney transplant recipients: a randomized clinical trial. JAMA. 2023;330(1):33–42. Epub 2023/06/07. doi: 10.1001/jama.2023.9106 PubMed PMID: 37279999; PubMed Central PMCID: PMCPMC10245286.
   PubMed Web of Science ®Google Scholar
• Kaur R, Purtill D, Cooney J, et al. Letermovir for pre-emptive cytomegalovirus therapy after allogeneic hematopoietic cell transplantation. Transpl Infect Dis. 2023;25(Suppl 1):e14147. Epub 2023/09/07. doi: 10.1111/tid.14147 PubMed PMID: 37676725.
   PubMedGoogle Scholar
• Robin C, Thiebaut A, Alain S, et al. Letermovir for secondary prophylaxis of cytomegalovirus infection and disease afteR allogeneic hematopoietic cell transplantation: results from the French compassionate program. Biology of blood and marrow transplantation. J Am Soc Blood Marrow Transplantation. 2020;26(5):978–984. Epub 2020/02/09. doi: 10.1016/j.bbmt.2020.01.027 PubMed PMID: 32035273.
   PubMed Web of Science ®Google Scholar
• Lin A, Maloy M, Su Y, et al. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: real-world experience. Transpl Infect Dis. 2019;21(6):e13187. Epub 2019/10/05. doi: 10.1111/tid.13187 PubMed PMID: 31585500; PubMed Central PMCID: PMCPMC8573720.
   PubMed Web of Science ®Google Scholar
• Sassine J, Khawaja F, Shank B, et al. Letermovir use in patients with relapsed or refractory hematological malignancies. Transplant Cell Ther. 2021;27(3):S346–S8. doi: 10.1016/S2666-6367(21)00446-2
   Google Scholar
• Boignard A, Augier C, Kheng M, et al. Letermovir use to treat complex cytomegalovirus reactivations in two heart transplant recipients. Antivir Ther. 2022;27(6):13596535221133619. Epub 2022/11/19. doi: 10.1177/13596535221133619 PubMed PMID: 36398571.
   Web of Science ®Google Scholar
• Phoompoung P, Ferreira VH, Tikkanen J, et al. Letermovir as salvage therapy for cytomegalovirus infection in transplant recipients. Transplantation. 2020;104(2):404–409. Epub 2020/01/31. doi: 10.1097/tp.0000000000002785 PubMed PMID: 32000236.
   PubMed Web of Science ®Google Scholar
• Veit T, Munker D, Barton J, et al. Letermovir in lung transplant recipients with cytomegalovirus infection: a retrospective observational study. Am J Transplant. 2021;21(10):3449–3455. Epub 2021/06/13. doi: 10.1111/ajt.16718 PubMed PMID: 34118118.
   PubMed Web of Science ®Google Scholar
• Schubert L, Fisecker L, Thalhammer F, et al. Letermovir for the compassionate therapeutic use of cytomegalovirus infection. Eur J Clin Microbiol Infect Dis. 2021;40(2):435–439. Epub 2020/09/12. doi: 10.1007/s10096-020-03990-w PubMed PMID: 32914220; PubMed Central PMCID: PMCPMC7817558.
   PubMed Web of Science ®Google Scholar
• Turner N, Strand A, Grewal DS, et al. Use of letermovir as salvage therapy for drug-resistant cytomegalovirus retinitis. Antimicrobial agents and chemotherapy 2019;63(3). Epub 2019/01/16. doi: 10.1128/aac.02337-18 PubMed PMID: 30642941; PubMed Central PMCID: PMCPMC6395918.
   Web of Science ®Google Scholar
• Goldner T, Hempel C, Ruebsamen-Schaeff H, et al. Geno- and phenotypic characterization of human cytomegalovirus mutants selected in vitro after letermovir (AIC246) exposure. Antimicrob Agents Chemother. 2014;58(1):610–613. Epub 2013/11/06. doi: 10.1128/aac.01794-13 PubMed PMID: 24189264; PubMed Central PMCID: PMCPMC3910730.
   PubMed Web of Science ®Google Scholar
• Linder KA, Kovacs C, Mullane KM, et al. Letermovir treatment of cytomegalovirus infection or disease in solid organ and hematopoietic cell transplant recipients. Transpl Infect Dis. 2021;23(4):e13687. Epub 2021/07/13. doi: 10.1111/tid.13687 PubMed PMID: 34251742.
   PubMedGoogle Scholar
• Di Cristanziano V, Affeldt P, Trappe M, et al. Combined therapy with Intravenous Immunoglobulins, letermovir and (val-)ganciclovir in complicated courses of CMV-Infection in transplant recipients. Microorganisms. 2021;9(8). Epub 2021/08/28. 1666. doi: 10.3390/microorganisms9081666 PubMed PMID: 34442744; PubMed Central PMCID: PMCPMC8398864.
   PubMed Web of Science ®Google Scholar
• Jorgenson MR, Descourouez JL, Garg N, et al. The addition of adjunctive letermovir to valganciclovir for refractory cytomegalovirus viremia in kidney transplant recipients. Transpl Infect Dis. 2021;23(4):e13693. Epub 2021/07/27. doi: 10.1111/tid.13693 PubMed PMID: 34309158.
   PubMedGoogle Scholar
• Chen G, Herr M, Nowak J, et al. Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant. Haematologica. 2023;108(2):615–620. Epub 2022/10/21. doi: 10.3324/haematol.2022.281719 PubMed PMID: 36263844; PubMed Central PMCID: PMCPMC9890024.
   PubMed Web of Science ®Google Scholar
• Khawaja F, Prakash R, Sassine J, et al. Cytomegalovirus (CMV) reactivation within in the first year after chimeric antigen receptor (CAR) T cell therapy: experience from the first two years at a Major cancer center. Blood. 2022;140(Supplement 1):7533–7535. doi: 10.1182/blood-2022-167908
   Google Scholar
• Márquez-Algaba E, Iacoboni G, Pernas B, et al. Impact of cytomegalovirus replication in patients with aggressive B cell lymphoma treated with Chimeric Antigen Receptor T cell therapy. Transplant Cell Ther. 2022;28(12):.e851.1–.e.8. Epub 2022/10/13. doi: 10.1016/j.jtct.2022.09.007 PubMed PMID: 36221995.
   Google Scholar
• Lancman G, Parsa K, Rodriguez C, et al. Infections and severe hypogammaglobulinemia in multiple myeloma patients treated with anti-BCMA bispecific antibodies. Blood. 2022;140(Supplement 1):10073–10074. doi: 10.1182/blood-2022-163733
   Google Scholar
• Mazahreh F, Mazahreh L, Schinke C, et al. Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis. Blood Adv. 2023;7(13):3069–3074. Epub 2023/03/02. doi: 10.1182/bloodadvances.2022009435 PubMed PMID: 36857755; PubMed Central PMCID: PMCPMC10331406 interests.
   PubMed Web of Science ®Google Scholar